News Daiichi teams up with GAIA for cholesterol DTx in Europe Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.
News Orexo exits depression DTx alliance with GAIA Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.
News Orexo buys US rights to GAIA's deprexis digital therapeutic Sweden's Orexo has announced it has bought the exclusive US rights to GAIA’s deprexis, a digital therapy to help patients manage their symptoms of depression and one of the most researched
News Windward Bio catches $175m from its IPO Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.